Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Design of the EpiPen Auto-Injector.

Salmun LM, Cavanaugh PF Jr.

J Allergy Clin Immunol. 2013 Jul;132(1):248. doi: 10.1016/j.jaci.2013.04.021. Epub 2013 May 29. No abstract available.

PMID:
23726038
2.

Safety and efficacy of glycopyrrolate oral solution for management of pathologic drooling in pediatric patients with cerebral palsy and other neurologic conditions.

Zeller RS, Davidson J, Lee HM, Cavanaugh PF.

Ther Clin Risk Manag. 2012;8:25-32. doi: 10.2147/TCRM.S27362. Epub 2012 Jan 25.

3.
4.

Examination of the effect of increasing doses of etoricoxib on oral methotrexate pharmacokinetics in patients with rheumatoid arthritis.

Schwartz JI, Agrawal NG, Wong PH, Miller J, Bachmann K, Marbury T, Hoelscher D, Cavanaugh PF Jr, Gottesdiener K.

J Clin Pharmacol. 2009 Oct;49(10):1202-9. doi: 10.1177/0091270009338939.

PMID:
19783714
5.

Comparative inhibitory activity of etoricoxib, celecoxib, and diclofenac on COX-2 versus COX-1 in healthy subjects.

Schwartz JI, Dallob AL, Larson PJ, Laterza OF, Miller J, Royalty J, Snyder KM, Chappell DL, Hilliard DA, Flynn ME, Cavanaugh PF Jr, Wagner JA.

J Clin Pharmacol. 2008 Jun;48(6):745-54. doi: 10.1177/0091270008317590. Epub 2008 Apr 23.

PMID:
18434566
6.

Lack of effect of antacids on single-dose pharmacokinetics of etoricoxib.

Schwartz JI, Agrawal NG, Kher UA, DeSmet M, Cavanaugh PF Jr, Guillaume M, Ebel DL, Merschman SA, Wagner JA.

J Clin Pharmacol. 2007 Oct;47(10):1342-6. Epub 2007 Jul 26. No abstract available.

PMID:
17656618
7.

Pooled analysis of thrombotic cardiovascular events in clinical trials of the COX-2 selective Inhibitor etoricoxib.

Curtis SP, Ko AT, Bolognese JA, Cavanaugh PF, Reicin AS.

Curr Med Res Opin. 2006 Dec;22(12):2365-74.

PMID:
17265571
8.

Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women.

Block SL, Nolan T, Sattler C, Barr E, Giacoletti KE, Marchant CD, Castellsagué X, Rusche SA, Lukac S, Bryan JT, Cavanaugh PF Jr, Reisinger KS; Protocol 016 Study Group.

Pediatrics. 2006 Nov;118(5):2135-45.

PMID:
17079588
9.

Evaluation of the effect of perioperative rofecoxib treatment on pain control and clinical outcomes in patients recovering from gynecologic abdominal surgery: a randomized, double-blind, placebo-controlled clinical study.

Sinatra RS, Boice JA, Loeys TL, Ko AT, Kashuba MM, Jahr JS, Rhondeau S, Singla N, Cavanaugh PF Jr, Reicin AS; Protocol 159 Study Group.

Reg Anesth Pain Med. 2006 Mar-Apr;31(2):134-42.

PMID:
16543099
10.

Immunogenicity and reactogenicity of a novel vaccine for human papillomavirus 16: a 2-year randomized controlled clinical trial.

Poland GA, Jacobson RM, Koutsky LA, Tamms GM, Railkar R, Smith JF, Bryan JT, Cavanaugh PF Jr, Jansen KU, Barr E.

Mayo Clin Proc. 2005 May;80(5):601-10.

PMID:
15887427
11.

Efficacy of cyclo-oxygenase-2 inhibition by etoricoxib and naproxen on the axial manifestations of ankylosing spondylitis in the presence of peripheral arthritis.

Gossec L, van der Heijde D, Melian A, Krupa DA, James MK, Cavanaugh PF, Reicin AS, Dougados M.

Ann Rheum Dis. 2005 Nov;64(11):1563-7. Epub 2005 Feb 24.

12.

Etoricoxib.

Matsumoto AK, Cavanaugh PF Jr.

Drugs Today (Barc). 2004 May;40(5):395-414. Review.

PMID:
15319795
13.

Randomized, double-blind, placebo-controlled phase IIb trial of the cyclooxygenase inhibitor ketorolac as an oral rinse in oropharyngeal leukoplakia.

Mulshine JL, Atkinson JC, Greer RO, Papadimitrakopoulou VA, Van Waes C, Rudy S, Martin JW, Steinberg SM, Liewehr DJ, Avis I, Linnoila RI, Hewitt S, Lippman SM, Frye R, Cavanaugh PF Jr.

Clin Cancer Res. 2004 Mar 1;10(5):1565-73.

14.

The overexpression of cyclo-oxygenase-2 in chronic periodontitis.

Zhang F, Engebretson SP, Morton RS, Cavanaugh PF Jr, Subbaramaiah K, Dannenberg AJ.

J Am Dent Assoc. 2003 Jul;134(7):861-7.

PMID:
12892443
15.

Relationship between age, renal function and bone mineral density in the US population.

Klawansky S, Komaroff E, Cavanaugh PF Jr, Mitchell DY, Gordon MJ, Connelly JE, Ross SD.

Osteoporos Int. 2003 Jul;14(7):570-6. Epub 2003 Jul 3.

PMID:
12844211
16.

Cyclooxygenase regulates human oropharyngeal carcinomas via the proinflammatory cytokine IL-6: a general role for inflammation?

Hong SH, Ondrey FG, Avis IM, Chen Z, Loukinova E, Cavanaugh PF Jr, Van Waes C, Mulshine JL.

FASEB J. 2000 Aug;14(11):1499-507.

PMID:
10928984
18.

Development of a MIMIC-based polymerase chain reaction technique for the analysis of prostaglandin endoperoxide H synthase isoenzyme cDNAs.

Zimmermann N, Cavanaugh PF Jr, Doney MK, Haq N, Gluckman JL, Pavelic ZP.

Anal Biochem. 1997 Aug 15;251(1):110-3. No abstract available.

PMID:
9300090
19.

Prostaglandin H synthase isoenzyme distribution in the gingival tissue of patients with periodontitis: pronounced expression adjacent to gram-positive bacteria.

McDonald JS, Cavanaugh PF, Pavelic LJ, Limardi RJ, Gluckman JL, Pavelic ZP.

Inflammopharmacology. 1997;5(2):109-18.

PMID:
17694359
20.

Validation of quantitative digital subtraction radiography using the electronically guided alignment device/impression technique.

Hausmann E, Allen K, Loza J, Buchanan W, Cavanaugh PF Jr.

J Periodontol. 1996 Sep;67(9):895-9.

PMID:
8884647
21.

Efficacy of quantitative digital subtraction radiography using radiographs exposed in a multicenter trial.

Jeffcoat MK, Reddy MS, Magnusson I, Johnson B, Meredith MP, Cavanaugh PF Jr, Gerlach RW.

J Periodontal Res. 1996 Apr;31(3):157-60.

PMID:
8814584
22.

The activation of murine macrophages and natural killer cells by the partially thiolated double stranded RNA poly(I)-mercapto poly(C).

Cavanaugh PF Jr, Ho YK, Bardos TJ.

Res Commun Mol Pathol Pharmacol. 1996 Feb;91(2):131-47.

PMID:
8832906
23.

A semi-automated neutral red based chemosensitivity assay for drug screening.

Cavanaugh PF Jr, Moskwa PS, Donish WH, Pera PJ, Richardson D, Andrese AP.

Invest New Drugs. 1990 Nov;8(4):347-54.

PMID:
2084068
24.

Structural determinants of spermidine-DNA interactions.

Vertino PM, Bergeron RJ, Cavanaugh PF Jr, Porter CW.

Biopolymers. 1987 May;26(5):691-703. No abstract available.

PMID:
3593890
25.

Characterization of L1210 cell growth inhibition by the bacterial iron chelators parabactin and compound II.

Cavanaugh PF Jr, Porter CW, Tukalo D, Frankfurt OS, Pavelic ZP, Bergeron RJ.

Cancer Res. 1985 Oct;45(10):4754-9.

26.

Biological properties of N4- and N1,N8-spermidine derivatives in cultured L1210 leukemia cells.

Porter CW, Cavanaugh PF Jr, Stolowich N, Ganis B, Kelly E, Bergeron RJ.

Cancer Res. 1985 May;45(5):2050-7.

28.

Antineoplastic and antiherpetic activity of spermidine catecholamide iron chelators.

Bergeron RJ, Cavanaugh PF Jr, Kline SJ, Hughes RG Jr, Elliott GT, Porter CW.

Biochem Biophys Res Commun. 1984 Jun 29;121(3):848-54.

PMID:
6331431
29.

Selectivity of antitemplates as inhibitors of deoxyribonucleic acid polymerases.

Cavanaugh PF Jr, Ho YK, Hughes RG Jr, Bardos TJ.

Biochem Pharmacol. 1982 Dec 15;31(24):4055-60.

PMID:
6297506
30.

Dilemmas of experimentation on children.

Cavanaugh PF.

Linacre Q. 1977 Aug;44(3):273-7. No abstract available.

PMID:
11660908

Supplemental Content

Loading ...
Support Center